Replies to post #228573 on Cytodyn Inc (CYDY)

[misiu143]

There is not much new in this article , but a good review of our last conference ..

What is happening now in the company , and plans for the near future .

And I like those plans for a near future .

—Finalization , and hopefully soon after acceptance of a protocol for our immune activation , inflammation study ..
With approval of a protocol this new full hold will be remove .
Plan for a study to start is this summer , so I believe all should be approved much sooner ..
They want 50% to be trans women with HIV , I was little worry how easy will be to enroll so many , but at the end my friends and I decided that Dr Jay is working with HIV population in San Francisco for so long , he must know it will be possible if that’s what he want to do .

— they want to do ASAP peer review and publish few studies we did .
Dr Jay ,as we can see in his talks , like my physicians friends and I think , that 82% mortality benefit above ALL drugs for critical Covid is unusual and great , and this should be done long time ago ..
And one may only think how many lives would be saved if only FDA give EUA for this indication , as they should imo .at the time .
Rumor is NIH doctors were very interested with this 82% number , and I believe dr Jay said on the CC that when this will be peer reviewed ,and published , it will be send to NIH .

They will also be doing work to peer review and publish other studies .
—Our CD02 - hiv combo , results were unbelievable ,
81% efficacy when only 2 other drugs approved for these patients at this time were
Maraviroc with 45% snd Ibalizumab with 43%
—also for cancer and Nash

We have a lot to be proud with Leronlimab , but since none of this was done until now , only the shareholders really know how unusual and great drug leronlimab is ..

So hopefully 2024 will be again this exciting year for us here .

All imo

GLTA longs